Journal updates

OCEAN(a)-DOSE trial shows olpasiran reduces OxPL-apoB 

February 18, 2025

Olpasiran significantly reduces apoB-associated oxidised phospholipids (OxPL-apoB), according to results of a pre-specified analysis of data from the Phase 2 OCEAN(a)-DOSE trial.  

Will anti-inflammatory therapies help patients with high Lp(a)?  

February 10, 2025

Anti-inflammatory treatments may provide additional therapeutic benefits for individuals with high Lp(a), suggest Professor Winfried Marz (pictured left) and colleagues in the light of results from the Ludwigshafen Risk and Cardiovascular Health (LURIC) study evaluating the effects of Lp(a), hsCRP, and interleukin-6 (IL-6) levels on cardiovascular mortality. 

UK lipid guidance recommends Lp(a) measurement in enhanced lipid profiling

January 22, 2025

New UK lipid guidance recommends Lp(a) measurement to be included in enhanced lipid profiling for patients with a personal or family history of premature atherosclerotic cardiovascular disease (ASCVD), first-degree relatives with raised serum Lp(a), familial hypercholesterolemia (FH) or other genetic dyslipidaemias, calcific aortic valve stenosis, or a moderate (10-15%) 10-year risk of a cardiovascular event.

Apo(a) isoform size affects Lp(a) response to lipid lowering therapy 

January 15, 2025

People with larger apo(a) size have the greatest reduction in Lp(a) level in response to potent lipid lowering therapy (LLT). This was one of the findings from the Phase 4 CHOlesterol Reduction and Residual Risk in Diabetes (CHORD) study in which participants with LDL-C >100 mg/dL with and without diabetes (DM) received LLT for 30 […]

Elevated Lp(a) linked to MACE independently of hs-CRP level 

January 6, 2025

Elevated Lp(a) is associated with an increased risk of major adverse cardiovascular events (MACE) independently of hs-CRP level in both primary and secondary prevention populations. This is the conclusion from a systematic review and meta analysis of data from 11 studies, involving 562,301 participants, that reported the relationship between Lp(a) and MACE, stratified by hs-CRP […]

Zerlasiran and muvalaplin studies published 

December 31, 2024

Results of Phase 2 studies of zerlasiran and muvalaplin in patients with elevated Lp(a) and atherosclerotic cardiovascular disease (ASCVD) have been published.